Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesRenovoRx Inc

RenovoRx Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.215 USD 0.04 ( 2.97%)
Last update at 2026-11-11T20:58:00Z
VOLUME
241891
Market Cap
30.42M

Momentum Score

…

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.12
Low
1.26
High
52 Week Price Range
0.53
Low
3.29
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

RenovoRx Inc develops a catheter-based platform for regional delivery of cancer therapeutics to solid tumors, aiming to increase local drug exposure while limiting systemic toxicity. Long-term growth drivers include adoption by interventional oncology centers, partnerships for commercialization, and potential expansion into multiple tumor indications, which may benefit investors if real-world use supports clinical value.
Material risks include clinical and regulatory uncertainty, limited operating history and revenue, ongoing capital requirements, and competition from systemic and other locoregional cancer therapies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.18
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.19
ROE
-320.57%
Net Debt
-1.17M
ROCE
-3421.31%
Diluted EPS TTM
-0.71

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -9.89M -6.32M -3.80M -3.84M
Net income -9.77M -7.10M -4.38M -3.78M
Selling general administrative 5.65M 2.63M 0.82M 0.90M
Reconciled depreciation 0.01M 0.01M - -
Ebit -9.96M -5.67M -3.20M -3.90M
Ebitda -9.95M -5.72M -3.21M -3.83M
Depreciation and amortization 0.01M -0.05M -0.00M 0.07M
Operating income -9.95M -5.67M -3.20M -3.90M
Other operating expenses 9.95M 5.67M 3.20M 3.90M
Interest expense 0.06M 0.83M 0.59M 0.00M
Interest income 0.06M - 0.00M 0.06M
Net interest income 0.06M -0.83M -0.59M 0.06M
Income tax expense -0.12M 0.77M 0.59M -0.06M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 9.95M 5.67M 3.20M 3.90M
Total other income expense net 0.06M -0.65M -0.59M 0.06M
Net income from continuing ops -9.89M -6.32M -3.80M -3.84M
Net income applicable to common shares -9.89M -6.32M -3.80M -3.84M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1.47M 7.26M 16.29M 1.91M 2.27M
Other current assets 0.19M 0.82M 1.09M 0.12M 0.14M
Total liab 4.47M 1.10M 0.94M 16.57M 13.20M
Total stockholder equity -3.00M 6.16M 15.35M -14.66M -10.93M
Other current liab 0.61M 0.57M 0.41M 0.86M 0.27M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -41.41M -31.17M -21.28M -14.96M -11.16M
Other assets -0.10M - - 0.00M 0.00M
Cash 1.17M 6.44M 15.19M 1.79M 2.10M
Total current liabilities 1.18M 1.10M 0.94M 4.10M 0.81M
Current deferred revenue - - - 0.31M -
Net debt -1.17M -6.44M -15.19M 0.99M -2.10M
Short term debt - - - 2.77M -
Short long term debt - - - 2.77M -
Short long term debt total - - - 2.79M -
Other stockholder equity 38.40M 31.16M 36.63M 0.30M 0.23M
Property plant equipment - - 0.01M - -
Total current assets 1.47M 7.26M 16.28M 1.91M 2.27M
Net tangible assets - 8.15M 15.35M -14.66M -10.93M
Short term investments 0.00M 2.05M - - -
Long term debt - - - 0.02M -
Accounts payable 0.56M 0.53M 0.53M 0.16M 0.54M
Accumulated other comprehensive income 3.00M 0.02M -16.29M - -
Common stock total equity - - - 0.00M 0.00M
Non currrent assets other 0.10M - 0.01M 0.00M 0.00M
Non current assets total 0.10M 0.00M 0.01M 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -2.03M -0.01M -2.03M -0.00M
Change to liabilities 0.00M 0.36M -0.38M 0.34M
Total cashflows from investing activities -2.03M -0.01M -0.01M -0.00M
Net borrowings - 1.98M 3.18M 3.18M
Total cash from financing activities 0.04M 19.33M 3.20M 3.20M
Change to operating activities 0.42M -0.63M 0.11M 0.10M
Net income -9.89M -6.32M -3.80M -3.84M
Change in cash -10.80M 13.40M -0.33M -3.35M
Begin period cash flow 15.19M 1.79M 2.12M 5.47M
End period cash flow 4.39M 15.19M 1.79M 2.12M
Total cash from operating activities -8.81M -5.92M -3.53M -3.35M
Issuance of capital stock 0.00M 14.56M - -
Depreciation 0.01M 0.01M 0.01M 0.01M
Other cashflows from investing activities - - - -0.00M
Other cashflows from financing activities 0.04M 4.76M 3.20M -0.00M
Change to netincome - -0.03M 0.05M 0.05M
Capital expenditures 0.00M 0.01M 0.01M 0.01M
Change in working capital 0.43M -0.27M -0.27M 0.44M
Stock based compensation 0.64M 0.15M 0.05M 0.04M
Other non cash items -0.01M 0.70M 0.49M 0.01M
Free cash flow -8.81M -5.93M -3.53M -3.35M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RNXT
RenovoRx Inc		 0.04
2.97%		 1.22 - - - 3365.40 -1.70
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

RenovoRx Inc

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

4546 El Camino Real, Los Altos, CA, United States, 94022

650 284 4433

https://renovorx.com

10

Name Title Year Born
Mr. Shaun R. Bagai CEO & Director 1978
Mr. James M. Ahlers Chief Financial Officer 1964
Ms. Angela Gill Nelms Chief Operating Officer NA
Dr. Ramtin Agah M.D. Founder, Chairman of Board & Chief Medical Officer 1967
Mr. Ronald B. Kocak CPA VP & Controller NA
Mr. Shaun R. Bagai CEO & Director 1977
Mr. Ronald B. Kocak CPA, CGMA VP, Controller & Principal Accounting Officer 1957
Ms. Leesa Gentry Chief Clinical Officer 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…